Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Protagonist Therapeutics Inc Market Cap
Based on ratings from 4 stock analysts, the Protagonist Therapeutics Inc stock price is expected to increase by 12.85% in 12 months. This is calculated by using the average 12-month stock price forecast for Protagonist Therapeutics Inc. The lowest target is $43 and the highest is $60. Please note analyst price targets are not guaranteed and could be missed completely.
About 4 Wall Street analysts have assigned PTGX 4 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Protagonist Therapeutics Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on PTGX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of PTGX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Douglas Tsao HC Wainwright & Co. | Buy | $50 | Maintains | Sep 12, 2024 |
| Srikripa Devarakonda Truist Securities | Buy | $60 | Initiates | Sep 9, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $40 | Maintains | Aug 7, 2024 |
| Jonathan Wolleben JMP Securities | Market Outperform | $43 | Maintains | Aug 7, 2024 |
| Brian Cheng JP Morgan | Overweight | $48 | Maintains | Jul 25, 2024 |
| Julian Harrison BTIG | Buy | $51 | Maintains | Jul 24, 2024 |
| Jonathan Wolleben JMP Securities | Market Outperform | $45 | Reiterates | Jun 17, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $38 | Reiterates | Jun 14, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $38 | Reiterates | May 9, 2024 |
| Jonathan Wolleben JMP Securities | Market Outperform | $45 | Maintains | May 8, 2024 |
| Jonathan Wolleben JMP Securities | Market Outperform | $42 | Reiterates | Mar 11, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $38 | Maintains | Mar 11, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $38 | Reiterates | Feb 28, 2024 |
| Brian Cheng JP Morgan | Overweight | $37 | Maintains | Feb 28, 2024 |
| Jonathan Wolleben JMP Securities | Market Outperform | $37 | Maintains | Nov 3, 2023 |
| Tim Chiang Capital One | Overweight | Initiates | Oct 30, 2023 | |
| Douglas Tsao HC Wainwright & Co. | Buy | $38 | Reiterates | Oct 10, 2023 |
| Brian Cheng JP Morgan | Overweight | $34 | Maintains | Sep 25, 2023 |
| Douglas Tsao HC Wainwright & Co. | Buy | $38 | Reiterates | Aug 4, 2023 |
| Douglas Tsao HC Wainwright & Co. | Buy | $38 | Reiterates | Jul 10, 2023 |
When did it IPO
2016
Staff Count
125
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Dinesh V. Patel Ph.D.
Market Cap
$2.77B
In 2023, PTGX generated $60.0M in revenue, which was a increase of 125.73% from the previous year. This can be seen as a signal that PTGX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 10 Sep 2024
Sentiment - POSITIVE
Source - Benzinga
Summary - Truist Securities has started coverage on Protagonist Therapeutics (PTGX), highlighting its promising Phase 2 data for a rare blood cancer treatment and significant market potential.
Why It Matters - Truist's coverage initiation highlights Protagonist's promising drug potential and significant market opportunity, which could lead to increased investor interest and stock value.
Tue, 03 Sep 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Protagonist Therapeutics, Inc. (NASDAQ:PTGX) announced a leadership update with Dinesh V. Patel, Ph.D. involved. Further details on his role were not provided in the excerpt.
Why It Matters - Protagonist Therapeutics' leadership changes can impact company strategy and stock performance, influencing investor confidence and market perception.
Tue, 06 Aug 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Protagonist Therapeutics expects Phase 3 trial results for JNJ-2113 in psoriasis and ulcerative colitis by Q4 2024. Rusfertide data shows promising results in polycythemia vera; cash runway through 2027.
Why It Matters - Upcoming clinical trial results for JNJ-2113 and rusfertide could significantly impact Protagonist Therapeutics' stock value. Strong results may attract investment, while failures could lead to declines.
Tue, 06 Aug 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - Protagonist Therapeutics (PTGX) reported a quarterly loss of $0.50 per share, matching the Zacks Consensus Estimate and improving from a loss of $0.68 per share a year earlier.
Why It Matters - Protagonist Therapeutics' loss narrowing indicates improved financial performance, aligning with expectations, which may boost investor confidence and impact stock valuation.
Wed, 31 Jul 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Protagonist Therapeutics appointed Dr. Newman Yeilding as Chief Scientific Advisor, effective August 1, 2024. He joins from Janssen with extensive R&D and commercialization experience.
Why It Matters - The appointment of Dr. Yeilding, with his extensive R&D and commercialization experience, signals Protagonist's potential for innovation and growth in the immunology sector, impacting investor confidence.
Mon, 22 Jul 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Protagonist Therapeutics, Inc. (NASDAQ:PTGX) announced leadership changes with Dinesh V. Patel, Ph.D., taking a significant role on July 22, 2024.
Why It Matters - The announcement of Dinesh V. Patel's involvement could signal leadership changes or strategic shifts at Protagonist Therapeutics, impacting investor confidence and stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
